ZZZhong Zhang

Zhong Zhang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Zhong Zhang has a total of 60 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Risk stratification of IDH-wildtype glioblastoma: Deep learning on histopathology images and biological interpretation

    by Zeyu Ma, Zilong Wang, Bokai Zhao, Weiwei Wang, Dingyuan Su, Sen Li, Yuchen Ji, Dongming Yan, Zhong Zhang, Fangang Meng, et al.

  • Open Access

    Effect of intraoperative esketamine on moderate-to-severe depressive symptoms in major surgery patients: A randomized clinical trial

    by Yang Zhou, Wanchen Sun, Yuxuan Fu, Anxin Wang, Huan Zhang, Hongyu Tan, Wei Liu, Zhong Zhang, Wei Zhang, Gang Wang, et al.


  • Open Access

    Integrative analysis identified the key role of LAG3 in T cell exhaustion in glioma

    by Zheng Wang, Haitao Fu, Yuwei Li, Zewei Liu, Wenhua Fan, Yuqing Liu, Chuanbao Zhang, Jingshan Liang, Zhong Zhang, Liyun Zhong, et al.

    Lymphocyte-activation gene 3 (LAG3) is an immune checkpoint expressed on the surface of T cells. We conducted a comprehensive molecular characterization and clinical analysis of LAG3 expression in gliomas. Across the CGGA and TCGA glioma datasets, we observed that LAG3 expression increased with higher glioma grade. Further investigation into the molecular subtypes revealed that LAG3 exhibited the highest expression in the Mesenchymal subtype, similar to other immune checkpoints. CIBERSORT analysis showed a significant positive correlation between LAG3 expression and macrophages, suggesting LAG3’s involvement in shaping the immune microenvironment. Single-cell data indicated that LAG3 expression appeared to be complementary pattern to other immune checkpoints, implying multiple mechanisms of T cell exhaustion. Importantly, clinical data analysis demonstrated that elevated LAG3 expression is an independent poor prognostic factor for patient survival. These findings suggest that LAG3 may play a crucial role in regulating the immune microenvironment in gliomas and contribute to T cell exhaustion, alongside other immune checkpoints such as the PD-L1/PD-1 pathway. As such, LAG3 represents a potential therapeutic target for glioma immunotherapy.


  • Open Access

    Integrative analysis identified the key role of LAG3 in T cell exhaustion in glioma

    by Zheng Wang, Haitao Fu, Yuwei Li, Zewei Liu, Wenhua Fan, Yuqing Liu, Chuanbao Zhang, Jingshan Liang, Zhong Zhang, Liyun Zhong, et al.

    Lymphocyte-activation gene 3 (LAG3) is an immune checkpoint expressed on the surface of T cells. We conducted a comprehensive molecular characterization and clinical analysis of LAG3 expression in gliomas. Across the CGGA and TCGA glioma datasets, we observed that LAG3 expression increased with higher glioma grade. Further investigation into the molecular subtypes revealed that LAG3 exhibited the highest expression in the Mesenchymal subtype, similar to other immune checkpoints. CIBERSORT analysis showed a significant positive correlation between LAG3 expression and macrophages, suggesting LAG3's involvement in shaping the immune microenvironment. Single-cell data indicated that LAG3 expression appeared to be exclusive to other immune checkpoints, implying multiple mechanisms of T cell exhaustion. Importantly, clinical data analysis demonstrated that elevated LAG3 expression is an independent poor prognostic factor for patient survival. These findings suggest that LAG3 may play a crucial role in regulating the immune microenvironment in gliomas and contribute to T cell exhaustion, alongside other immune checkpoints such as the PD-L1/PD-1 pathway. As such, LAG3 represents a potential therapeutic target for glioma immunotherapy.

  • Open Access

    The clinical, radiological, and surgical characteristics of anterior perforated substance glioma: a retrospective study

    by Zhiliang Wang, Lianwang Li, Zheng Wang, Xuzhu Chen, Zhong Zhang

    Background: To explore the clinical, radiological, and surgical characteristics of anterior perforated substance (APS) gliomas. Methods: Twenty patients with APS glioma who were treated with surgery between March 2019 and January 2022 from Tiantan hospital were retrospectively reviewed. The clinical, histological and radiological data were collected. Results: Twenty patients, including 7 males (55%) and 13 females (45%), with a mean age at diagnosis of 37.9 years (range, 28–53 years) underwent operative intervention for APS. Headaches and dizziness were the most common preoperative symptoms in the majority patients (14, 70%). Based on radiological features of MRI, the APS was classified into two subtypes, type A and type B. Seven patients (40%) in type A indicated a clear tumor margin, while 13 patients (60%) in type B showed an ill-defined margin. The surgical approach including frontal, temporal, and coronal frontal incisions for type A and type B tumors, respectively. Three patients in type A received total resection, while one patient in type B were total resected. Pathologically, 12 cases (60%, 12/20) were diagnosed as astrocytoma and 8 cases (20%, 8/20) were oligodendroglioma. Meanwhile, 17 cases (85%, 17/20) had MGMT promotor methylation. Conclusion: In this study, we performed the first systematic research of patients with APS glioma. Most of patients with APS presented headaches and dizziness symptoms. The APS glioma was further divided into two major radiological subtypes with relevant different surgical approaches. The APS glioma in type A were more likely to receive total resection.

  • Open Access

    Development of an integrated predictive model for postoperative glioma-related epilepsy using gene-signature and clinical data

    by Lianwang Li, Chuanbao Zhang, Zheng Wang, Yinyan Wang, Yuhao Guo, Chong Qi, Gan You, Zhong Zhang, Xing Fan, Tao Jiang

    Background: This study aimed to develop an integrated model for predicting the occurrence of postoperative seizures in patients with diffuse high-grade gliomas (DHGGs) using clinical and RNA-seq data. Methods: Patients with DHGGs, who received prophylactic anti-epileptic drugs (AEDs) for three months following surgery, were enrolled into the study. The patients were assigned randomly into training (n = 166) and validation (n = 42) cohorts. Differentially expressed genes (DEGs) were identified based on preoperative glioma-related epilepsy (GRE) history. Least absolute shrinkage and selection operator (LASSO) logistic regression analysis was used to construct a predictive gene-signature for the occurrence of postoperative seizures. The final integrated prediction model was generated using the gene-signature and clinical data. Receiver operating characteristic analysis and calibration curve method were used to evaluate the accuracy of the gene-signature and prediction model using the training and validation cohorts. Results: A seven-gene signature for predicting the occurrence of postoperative seizures was developed using LASSO logistic regression analysis of 623 DEGs. The gene-signature showed satisfactory predictive capacity in the training cohort [area under the curve (AUC) = 0.842] and validation cohort (AUC = 0.751). The final integrated prediction model included age, temporal lobe involvement, preoperative GRE history, and gene-signature-derived risk score. The AUCs of the integrated prediction model were 0.878 and 0.845 for the training and validation cohorts, respectively. Conclusion: We developed an integrated prediction model for the occurrence of postoperative seizures in patients with DHGG using clinical and RNA-Seq data. The findings of this study may contribute to the development of personalized management strategies for patients with DHGGs and improve our understanding of the mechanisms underlying GRE in these patients.


  • Open Access

    Characteristic Alterations of Network in Patients With Intraoperative Stimulation-Induced Seizures During Awake Craniotomy

    by Shengyu Fang, Chunyao Zhou, Lei Wang, Xing Fan, Yinyan Wang, Zhong Zhang, Tao Jiang

    Background: The use of electrocorticography (ECoG) to avoid intraoperative stimulation-induced seizure (ISS) during awake craniotomy is controversial. Although a standard direct cortical stimulating (DCS) protocol is used to identify the eloquent cortices and subcortical structures, ISS still occurs. Epilepsy is related to alterations in brain networks. In this study, we investigated specific alterations in brain networks in patients with ISS.Methods: Twenty-seven patients with glioma were enrolled and categorized into the ISS and non-ISS groups based on their history of ISS occurrence. A standard DCS protocol was used during awake craniotomy without ECoG supervision. Graph theoretical measurement was used to analyze resting-state functional magnetic resonance imaging data to quantitatively reveal alterations in the functional networks.Results: In the sensorimotor networks, the glioma significantly decreased the functional connectivity (FC) of four edges in the ISS group, which were conversely increased in the non-ISS group after multiple corrections (p < 0.001, threshold of p-value = 0.002). Regarding the topological properties, the sensorimotor network of all participants was classified as a small-world network. Glioma significantly increased global efficiency, nodal efficiency, and the sigma value, as well as decreased the shortest path length in the ISS group compared with the non-ISS group (p < 0.05).Conclusions: The specific alterations indicating patient susceptibility to ISS during DCS increased global and nodal efficiencies and decreased the shortest path length and FC induced by gliomas. If the patient has these specific alterations, ECoG is recommended to monitor after-discharge current during DCS to avoid ISS.


  • Awake craniotomy for gliomas involving motor-related areas: classification and function recovery

    by Shengyu Fang, Yiming Li, Yinyan Wang, Zhong Zhang, Tao Jiang

    Purpose Motor mapping with direct cortical stimulation (DCS) is useful for motor function preservation. Nevertheless, many patients still experience postoperative motor dysfunction after motor mapping. This study aimed to provide a classification of gliomas involved in motor-related areas to help understand which types of gliomas are prone to induce postoperative motor impairments. Methods Sixty-four patients were retrospectively recruited. Based on tumor location, four types of gliomas were identified: (I) precentral gyrus; (II) premotor and/or supplementary motor areas but not invading pre-central gyrus; (III) adjacent to the posterior limb of the internal capsule; and (IV) other supra-tentorial area. The recovery of motor function was evaluated by muscle strength testing before surgery and 3 days, 7 days, 14 days, and 3 months after surgery. Results Half of the patients experienced postoperative transient motor impairment within a week. Six patients suffered from permanent motor dysfunction, and four of them had type III glioma. Compared with types I and IV, patients with type III gliomas took more than three times as long to recover. Furthermore, patients with types I and II gliomas were more susceptible to preoperative epilepsy than those with types III and IV. There was no difference in postoperative seizure control between the four types. Conclusions Our classification of gliomas involving motor-related eloquent areas was useful for predicting postoperative motor functional prognosis in patients who underwent motor mapping with DCS. Even if no positive sites were detected, a conservative strategy of tumor resection is recommended in cases that gliomas located close to the posterior limb of the internal capsule.


  • Open Access

    Long-term efficacy of surgical resection with or without adjuvant therapy for treatment of secondary glioblastoma in adults

    by Ruoyu Huang, Guanzhang Li, Yiming Li, Yinyan Wang, Pei Yang, Chuanbao Zhang, Zheng Wang, Dabiao Zhou, Wei Zhang, Zhong Zhang, et al.

    Background: There are limited studies on treatment strategies and associated clinical outcomes in patients with secondary glioblastoma (sGBM). We sought to investigate the prognostic factors and treatment decisions in a retrospective cohort of patients with sGBM. Methods: One hundred and seventy-one patients with sGBM who met the screening criteria were included in this study. Kaplan–Meier survival analysis and Cox survival analysis were used to detect prognostic factors. R (v3.5.0) and SPSS software (v25.0, IBM) were used to perform statistical analyses. Results: The median overall survival was 303 days (range 23–2237 days) and the median progression-free survival was 229 days (range 33–1964 days) in patients with sGBM. When assessing the relationship between adjuvant treatment outcome and extent of resection (EOR), the results showed that patients underwent gross total resection can benefit from postoperative radiotherapy and chemotherapy, but not in patients underwent subtotal resection. In addition, we also found that aggressive adjuvant therapy can significantly improve clinical outcomes of IDH1-mutated patients but no significant prognostic value for IDH1-wildtyped patients. The univariate Cox regression analyses demonstrated that EOR, adjuvant therapy, and postoperative Karnofsky Performance Scores were prognostic factors for patients with sGBM, and multivariate COX analysis confirmed that adjuvant therapy and EOR were independent prognostic factors. Conclusions: For patients with sGBM, aggressive postoperative adjuvant therapy after gross total resection was recommended. However, we did not detect a benefit in IDH1-wildtype patients in our cohort.